MedTrace Logo

Angiotensin II Antagonist in Severe Sepsis

NCT01992796 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2013-11-25

No results posted yet for this study

Summary

The investigators propose a clinical study of irbersartan for the early treatment of severe sepsis patients with elevated predicted risk of death between. This study will evaluate whether early administration of the the angiotensin receptor blocker irbersartan provides significant reduction of 28 days mortality and multi organ failure incidence to patients with severe sepsis.

Conditions

  • Severe Sepsis

Interventions

DRUG

Irbesartan

75 mg/per os/for 15 days

Sponsors & Collaborators

  • Federico II University

    collaborator OTHER

  • University of Salerno

    lead OTHER

Principal Investigators

  • Rosalba Tufano, MD · Federico II University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992796 on ClinicalTrials.gov